Risk of progression of early-stage mycosis fungoides, 10-year experience
Anais Brasileiros de Dermatologia · 2024
DOI: 10.1016/j.abd.2023.08.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anais Brasileiros de Dermatologia, 2024. Verfasst von Santiago Andrés Ariza Gómez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, University Foundation of Health Sciences, San José Hospital, Bogotá, Colombia. Hauptthemen laut MEDLINE: Mycosis Fungoides, Disease Progression, Skin Neoplasms, Neoplasm Staging. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Mycosis fungoides is the most frequent form of cutaneous T-cell lymphoma. It is characterized by a chronic, slow, and progressive course, and is associated with mortality rates that depend on several factors, such as clinical staging. A median survival time of up to 13 months is found in patients with advanced stages that require more aggressive treatments, with greater toxicity and higher costs. In Latin America, few prognostic studies of the disease are available.
Objective
To determine the rate of progression from early stages (IA, IB, IIA) to more advanced stages (> IIB) in patients older than 18 years with mycosis fungoides treated at two medical centers in Colombia between January 1, 2010, and December 31, 2019.
Methods
Retrospective cohort study with a longitudinal design.
Results
112 patients diagnosed with early mycosis fungoides were included. 56.2% were male (n = 63), with a median age of 53 years (IQR 43‒67). The most frequent clinical variant was classic (67.9%; n = 76), followed by folliculotropic (16%; n = 18), and hypopigmented (10.7%; n = 12). The most common first-line treatment was NB-UVB phototherapy (27.7%; n = 31), followed by PUVA phototherapy (25.8%; n = 29%), and topical corticosteroids (25%; n = 28). The global rate of disease progression was 8% (n = 9), with an overall mortality of 12.5% (n = 14). Study limitations Its retrospective design and the lack of molecular studies for case characterization.
Conclusions
Early mycosis fungoides is a disease with a good prognosis in most patients, with a progression rate of 8% (n = 9).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dermatology Department, University Foundation of Health Sciences, San José Hospital, Bogotá, Colombia.
- Dermatology Department, University Foundation of Health Sciences, San José Hospital, Bogotá, Colombia. Electronic address: padubeibe@fucsalud.edu.co.
Zitieren
APA
Ariza Gómez, S. A., Dubeibe Abril, P. A., Niebles Sincelejo, O. E., & Reina, H. S. L. (2024). Risk of progression of early-stage mycosis fungoides, 10-year experience. Anais Brasileiros de Dermatologia. https://doi.org/10.1016/j.abd.2023.08.008
Vancouver
Ariza Gómez SA, Dubeibe Abril PA, Niebles Sincelejo OE, Reina HSL. Risk of progression of early-stage mycosis fungoides, 10-year experience. Anais Brasileiros de Dermatologia. 2024. doi:10.1016/j.abd.2023.08.008
BibTeX
@article{ArizaGmez2024,
author = {Ariza Gómez, Santiago Andrés and Dubeibe Abril, Paula Alejandra and Niebles Sincelejo, Oscar Enrique and Reina, Henry Santiago Leal},
title = {Risk of progression of early-stage mycosis fungoides, 10-year experience},
journal = {Anais Brasileiros de Dermatologia},
year = {2024},
doi = {10.1016/j.abd.2023.08.008}
}
EUVIMED